

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
Investment Company Act of 1940

1. Name and Address of Reporting Person * Giladi Moshe	2. Date of Event Requiring Statement (MM/DD/YYYY) 7/26/2023	3. Issuer Name and Ticker or Trading Symbol NovoCure Ltd [NVCR]
(Last) (First) (Middle) C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Science Officer /	
(Street) WAYNE, PA 19087 (City) (State) (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	7,008	D	
Restricted Share Units	6,496 (1)	D	
Restricted Share Units	2,983 (2)	D	
Restricted Share Units	1,653 (3)	D	
Restricted Share Units	154 (4)	D	
Restricted Share Units	353 (5)	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options (Right to buy)	3/2/2024	3/1/2031	Ordinary Shares	1,951 (6)	\$153.09	D	
Stock Options (Right to buy)	11/2/2024	11/1/2031	Ordinary Shares	831 (7)	\$107.73	D	
Stock Options (Right to buy)	5/3/2024	5/2/2032	Ordinary Shares	7,693 (8)	\$83.77	D	
Stock Options (Right to buy)	3/1/2024	2/29/2032	Ordinary Shares	4,346 (9)	\$80.59	D	
Stock Options (Right to buy)	(10)	11/5/2029	Ordinary Shares	833	\$77.49	D	
Stock Options (Right to buy)	2/28/2024	2/27/2033	Ordinary Shares	10,804 (11)	\$76.97	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options (Right to buy)	3/3/2024	3/2/2030	Ordinary Shares	2,779 <u>(12)</u>	\$69.37	D	
Stock Options (Right to buy)	<u>(10)</u>	3/21/2029	Ordinary Shares	2,822	\$47.04	D	
Stock Options (Right to buy)	<u>(10)</u>	2/26/2028	Ordinary Shares	3,451	\$21.15	D	
Stock Options (Right to buy)	<u>(10)</u>	2/21/2027	Ordinary Shares	6,875	\$7.15	D	

Explanation of Responses:

- (1) Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
- (2) Represents restricted share units that are scheduled to vest in equal installments on May 3, 2024 and 2025, subject to the reporting person's continued employment through such dates.
- (3) Represents restricted share units that are scheduled to vest in equal installments on March 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.
- (4) Represents restricted share units that are scheduled to vest in equal installments on November 2, 2024, subject to the reporting person's continued employment through such date.
- (5) Represents restricted share units that are scheduled to vest in equal installments on March 2, 2024, subject to the reporting person's continued employment through such date.
- (6) Options to buy 1,951 ordinary shares, 976 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.
- (7) Options to buy 831 ordinary shares, 416 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.
- (8) Options to buy 7,693 ordinary shares, 1,924 shares of which are currently exercisable and the remainder will vest in equal installments on each of May 3, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
- (9) Options to buy 4,346 ordinary shares, 1,087 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
- (10) Currently exercisable.
- (11) Options to buy 10,804 ordinary shares will vest in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
- (12) Options to buy 2,779 ordinary shares, 2,085 shares of which are currently exercisable and the remainder will vest on March 3, 2024, subject to the reporting person's continued employment through such date.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Giladi Moshe C/O NOVOCURE INC. 1550 LIBERTY RIDGE DRIVE, SUITE 115 WAYNE, PA 19087			Chief Science Officer	

Signatures

Steven Robbins, as attorney in fact for Giladi, Moshe

12/20/2023

****Signature of Reporting Person**

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

**LIMITED POWER OF ATTORNEY
FOR
SECTION 16 REPORTING PURPOSES**

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Barak Ben-Arye, Steven Robbins, Ovie Onobrakpeya and Carrie Kane, individually, as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

- (1) execute for, and on behalf of, the undersigned, in the undersigned's capacity as an officer, director and/or 10% beneficial owner of Novocure Limited (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder (the "Exchange Act");
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to any attorneys-in-fact and further approves and ratifies any such release of information;
- (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare, complete and execute any such Form 3, 4 or 5, and any amendments thereto, or other required report and timely file such Forms or reports with the United States Securities and Exchange Commission, the New York Stock Exchange and any stock exchange or similar authority as considered necessary or advisable under Section 16(a) of the Exchange Act; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in such attorney-in-fact's sole discretion.

The undersigned hereby gives and grants to each such attorneys-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

The undersigned hereby acknowledges that

- (a) the foregoing attorneys-in-fact are serving in such capacity at the request of the undersigned; (b) this Limited Power of Attorney authorizes, but does not require, each such attorneys-in-fact to act in his or her discretion on information provided to such attorneys-in-fact without independent verification of such information; (c) any documents prepared and/or executed by any attorneys-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorneys-in-fact, in his or her sole discretion, deems necessary or advisable; (d) neither the Company nor any attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act,
 - (ii) any liability of the undersigned for any failure to comply with such requirements or
 - (iii) any obligation or liability of the undersigned for profit disgorgement under
- Section 16(b) of the Exchange Act; and (e) this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including, without limitation, the reporting requirements under Section 16 of the Exchange Act.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked as to any attorneys-in-fact by the undersigned in a signed writing delivered to such attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of December, 2023.

/s/ Moshe Giladi
Signature

Moshe Giladi
Print Name